- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Drug injections miss the mark in obese patients
Patients with large behinds do not derive the biggest benefit from vaccines and other injections into the buttocks, according to a study by Dr. Victoria Chan and colleagues at the Adelaide and Meath Hospital in Dublin, Ireland.
Patients with large behinds do not derive the biggest benefit from vaccines and other injections into the buttocks, according to a study by Dr. Victoria Chan and colleagues at the Adelaide and Meath Hospital in Dublin, Ireland.
Researchers observed 60 obese men and women scheduled for CT scans of the abdomen and pelvis who had received intramuscular medication. They found that 68% of intramuscular injections did not reach the buttock muscles.
The overall success rate of the injections was 32%. The success rate among men was 56% compared with only 8% among women. Compared with men, women typically have a higher amount of fat in their buttocks.
"The amount of fat tissue overlying the muscles exceeds the length of the needles commonly used for these injections," Chan said at the 2005 RSNA meeting.
Her solution? Longer needles.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
